– AUSTRIA, Vienna – Ribbon Biolabs, the DNA synthesis company, today announced the appointment of Roopom Banerjee as Executive Chairman of its Board of Directors, bringing 25 years of strategy, operations, business development, financial advisory, and investment experience in early and late-stage life science companies.
About Roopom Banerjee
Roopom Banerjee has held executive, management, and board positions at several US- and EU-based companies, including as CEO of RainDance Technologies, which pioneered next-generation sequencing and digital PCR for liquid biopsies. As Executive Chairman, he will draw on his investment experience and his company-scaling strategic expertise to help guide Ribbon’s growth to revolutionize and industrialize the manufacturing of synthetic DNA of unprecedented length and complexity for large market applications across the biomedical and life sciences industries.
Roopom Banerjee said: “Ribbon Biolabs is an emerging industry pioneer in synthetic biology, generating long error-free DNA molecules of unprecedented length and complexity, which has a tremendous potential impact on therapeutics development and biomedical research. I am excited to help the company through its next stage of commercialization and breakout growth. I look forward to supporting and guiding Ribbon’s talented and collaborative team, passionate about revolutionizing DNA synthesis.”
Roopom Banerjee is a seasoned industry leader who serves as a Managing Partner at WhiteLeaf Advisors LLC, guiding companies from the seed stage to successful exit. Additionally, he is a Senior Advisor at Bain Capital and an Operating Partner at CRG, where he actively advises on life science capital investments. He currently sits on several private and public company boards across life science tools, diagnostics, and therapeutics. Previously, he was President and CEO of RainDance Technologies (acquired by BioRad). Earlier in his career, he spent a decade on Wall Street at Goldman Sachs, McKinsey, and Leerink Swann, advising companies ranging from venture-backed life science startups to the Fortune 500 on strategy and financing. He has completed over 100 strategic advisory, financing, and investing transactions comprising over $200 billion in value, including 30 IPOs, 20 M&A transactions, and 15 private and public investments.
Mr. Banerjee holds two Bachelor of Science degrees in Biology and Economics from the Massachusetts Institute of Technology and a Master’s in Public Policy from the Kennedy School at Harvard University.
About Ribbon Biolabs
Ribbon Biolabs is a synthetic biology leader driving DNA synthesis beyond the limits of current technologies. With our automated, enzyme-based InfiniSynth platform, Ribbon Biolabs can provide DNA molecules without size or sequence limitations at a high level of accuracy and unprecedented speed. We are pioneering a highly differentiated approach to creating value for our partners and the next wave of innovation in the biopharmaceutical industry.
Source: https://ribbonbiolabs.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
